Shingles Vaccines Market Size, Share, and Growth Forecast 2026 - 2033

The global shingles vaccines market size is expected to be valued at US$6.5 billion in 2026 and projected to reach US$15.9 billion by 2033, growing at a CAGR of 13.7% during the forecast period from 2026 to 2033, driven by increasing awareness of herpes zoster and its complications, particularly postherpetic neuralgia, among the aging population. Recombinant vaccines, such as Shingrix, dominate owing to their higher efficacy and suitability for immunocompromised adults, surpassing traditional live-attenuated vaccines. Rising prevalence of chronic diseases, government initiatives to promote adult immunization, and growing demand for safe, effective, and accessible vaccines are expected to sustain market momentum over the forecast period.

Drivers - Increasing Incidence of Immunocompromised Patients

The rising prevalence of immunocompromised individuals is driving global demand for shingles vaccines. Patients undergoing organ transplants, chemotherapy, or long-term corticosteroid therapy have weakened immune systems, making them highly vulnerable to herpes zoster infection and its severe complications, including postherpetic neuralgia.

Awareness among healthcare providers about the elevated risk in these populations has prompted proactive vaccination recommendations. As a result, healthcare facilities increasingly prioritize shingles vaccination as a preventive measure for immunocompromised adults. This trend is especially prominent in developed markets with advanced healthcare infrastructure and targeted adult immunization programs, supporting sustained market growth.

Expanding Global Aging Population Increases At-Risk Cohort

The world's aging population continues expanding at a pace that directly enlarges the shingles vaccination target demographic. The World Health Organization projects the global population aged 60 and older will nearly double by 2050, reaching over 2.1 billion people. Since herpes zoster risk rises sharply with advancing age and declining immune function, this demographic expansion translates directly into growing vaccination demand across nearly every regional market. National immunization programs across North America, Europe, and parts of Asia Pacific continue expanding age-based eligibility criteria to capture this growing at-risk population. As life expectancy continues climbing across most global regions, manufacturers can reasonably anticipate structurally growing demand for shingles vaccination extending well beyond the current forecast horizon.

Restraints - High Vaccine Cost and Two-Dose Regimen Compliance Challenges

Recombinant shingles vaccination requires a two-dose regimen administered months apart, a structural requirement that introduces compliance risk. The Centers for Disease Control and Prevention has noted that second-dose completion rates lag behind first-dose uptake in several vaccination programs. Combined with relatively high per-dose pricing compared with many other adult immunizations, this cost and compliance burden can discourage completion among older adults facing fixed incomes or limited healthcare access, particularly across lower-income regions and uninsured population segments globally.

Side Effects and Safety Concerns

Shingles vaccines, particularly recombinant formulations such as Shingrix, are generally safe and effective, but side effects remain a key concern affecting patient adoption. Common reactions include pain, redness, or swelling at the injection site, mild fever, fatigue, headache, and muscle aches, usually resolving within a few days.

While these are temporary, they can cause discomfort and deter some patients, especially older adults. Rare but more serious reactions, such as severe allergic responses or neurological events, though extremely uncommon, further contribute to hesitancy among risk-averse individuals. Educating patients on the safety profile is essential to increase confidence and uptake.

Opportunities - Multi-Dose and Long-Lasting Formulations

The development of multi-dose or long-lasting shingles vaccines represents a significant opportunity to transform patient adherence and market dynamics. Traditional two-dose regimens often face challenges, including missed follow-ups, logistical complexities, and increased healthcare visits, which can limit real-world effectiveness.

By introducing vaccines that offer prolonged immunity with fewer doses or even a single-dose formulation, manufacturers can simplify vaccination schedules, improve completion rates, and enhance overall patient convenience. Such innovations also reduce storage and distribution burdens for healthcare providers, particularly in large-scale immunization programs.

Moreover, long-acting formulations provide differentiation in a competitive market, enabling premium positioning and greater adoption across both private and public healthcare segments, especially among aging populations seeking reliable, hassle-free protection.

Growth Potential across Immunocompromised Patient Populations

Expanding vaccination eligibility for immunocompromised adults represents a significant untapped opportunity for shingles vaccine manufacturers. The Advisory Committee on Immunization Practices has extended recombinant vaccination recommendations to immunocompromised adults as young as 19 years old, a population historically excluded from standard age-based eligibility criteria. This expanded eligibility meaningfully broadens the addressable patient population beyond the traditional geriatric cohort.

Companies including GlaxoSmithKline plc. and Merck & Co., Inc. continue supporting clinical research demonstrating vaccine safety and efficacy across various immunocompromising conditions. As oncology and transplant treatment centers increasingly incorporate shingles vaccination into standard care protocols for vulnerable patients, manufacturers positioned to support this specialized clinical demand stand to capture meaningful incremental growth beyond conventional age-based vaccination markets.

Product Type Analysis

Shingrix is projected to account for an 85% share of the global shingles vaccines market in 2026. This dominance reflects its strong clinical efficacy profile, with trial data demonstrating over 90% protection compared with considerably lower efficacy rates associated with older live attenuated vaccine alternatives. Following Merck & Co., Inc.'s discontinuation of U.S. distribution for Zostavax in 2020, market adoption has shifted significantly toward recombinant vaccine alternatives. GlaxoSmithKline plc. continues to expand Shingrix manufacturing capacity to address sustained global demand across multiple regions. Meanwhile, Sky Zoster is emerging as the fastest-growing product type through 2033, supported by SK bioscience Co., Ltd.'s efforts to expand distribution across Asian markets seeking domestically manufactured vaccination alternatives.

Vaccine Type Analysis

Recombinant vaccine formulations are expected to lead vaccine type segmentation, supported by clinical evidence showing substantially stronger and more durable immune protection compared with live attenuated alternatives. The Centers for Disease Control and Prevention recommends recombinant vaccination as the preferred option for nearly all eligible adults, reinforcing this segment's clinical and commercial leadership. Unlike live attenuated vaccines, recombinant formulations pose no risk of causing vaccine-strain infection in immunocompromised patients, broadening their eligible patient base considerably. This same safety and efficacy advantage also positions recombinant vaccines as the fastest-growing vaccine type through 2033, as remaining live attenuated formulations continue losing market share across nearly every global region following this clinical guidance shift.

Distribution Channel Analysis

Hospitals are expected to lead distribution channel segmentation, holding an estimated 45% share of the global shingles vaccines market in 2026. Hospital-based vaccination benefits from direct physician oversight and integration with existing patient care visits, particularly among older adults managing multiple chronic health conditions. Hospital pharmacy networks also maintain reliable cold-chain storage infrastructure required for vaccine stability. Meanwhile, Pharmacies represent the fastest-growing distribution channel, propelled by expanding pharmacist vaccination authority and the convenience of walk-in immunization access, allowing older adults to complete vaccination without scheduling dedicated physician appointments across increasingly accessible retail healthcare settings.

North America Shingles Vaccines Market Trends and Insights

North America remains the dominant region in the shingles vaccine market, driven by strong awareness of herpes zoster, high healthcare spending, and widespread adoption of adult immunization programs. The area benefits from robust access to recombinant vaccines, such as Shingrix, supported by large hospital networks and retail pharmacy chains that streamline vaccination delivery.

In the U.S., demand is particularly strong due to CDC recommendations for adults aged 50 and above and expanded guidelines for immunocompromised individuals. High insurance coverage, strong physician advocacy, and extensive public-health campaigns further accelerate uptake. Growing emphasis on preventing postherpetic neuralgia and increasing aging populations continue to make North America the most influential growth hub for shingles vaccination.

U.S. Shingles Vaccines Market Size

The U.S. represents the largest contributor to North American shingles vaccine demand, supported by strong vaccination recommendations from the Centers for Disease Control and Prevention, extensive pharmacy-based immunization access, and high healthcare awareness. Ongoing expansion of GlaxoSmithKline plc.’s Shingrix manufacturing capacity, along with broader vaccination eligibility for immunocompromised adults, continues to support steady market growth across the country.

Europe Shingles Vaccines Market Trends and Insights

Europe is projected to account for 24% of the global shingles vaccines market in 2026, supported by established adult immunization programs, favorable reimbursement systems, and widespread adoption of recombinant vaccines. Strong healthcare infrastructure, growing elderly populations, and evidence-based vaccination recommendations continue strengthening regional demand across major European countries for sustained long-term growth.

Germany and the United Kingdom remain key contributors through comprehensive vaccination policies, extensive healthcare coverage, and increasing awareness of herpes zoster prevention. Continued regulatory support, high physician confidence in recombinant vaccines, expanding vaccination access, and rising preventive healthcare adoption are expected to reinforce stable market expansion throughout the region.

Germany Shingles Vaccines Market Size

Germany is projected to account for 27% of the Europe shingles vaccines market in 2026, supported by robust healthcare infrastructure, comprehensive statutory health insurance, and national immunization recommendations promoting recombinant shingles vaccination for eligible older adults. Strong physician participation further encourages consistent vaccination uptake across the country.

Growing awareness of healthy aging, expanding preventive healthcare initiatives, and broad reimbursement coverage continue supporting vaccine demand. High healthcare expenditure, efficient vaccine distribution networks, favorable regulatory guidance, and increasing acceptance among aging populations are expected to strengthen Germany's leadership within the European shingles vaccines market.

U.K. Shingles Vaccines Market Size

The U.K. is expected to represent 21% of the Europe shingles vaccines market in 2026, driven by the National Health Service vaccination program and expanding eligibility for older adults. Well-established healthcare infrastructure and strong public health initiatives continue to support broad immunization coverage across the country.

Government-backed vaccination campaigns, increasing awareness of herpes zoster prevention, and streamlined vaccine delivery through primary care providers continue improving uptake. Continued investment in preventive healthcare, favorable immunization policies, and growing acceptance among elderly populations are anticipated to sustain the UK's strong position within the European regional market.

Asia Pacific Shingles Vaccines Market Trends and Insights

Asia Pacific shingles vaccine market is expanding rapidly due to rising aging populations, increasing burden of chronic diseases, and improving awareness of herpes zoster prevention. Countries such as Japan, China, South Korea, and Australia are driving adoption, supported by the growing availability of recombinant vaccines and strengthening adult immunization policies.

Local manufacturers, including SK Bioscience with Sky Zoster, are enhancing regional competition and accessibility. Expanding private healthcare infrastructure and higher out-of-pocket spending are further boosting vaccine uptake, especially in urban areas. As governments integrate shingles prevention into healthy-aging initiatives, the Asia Pacific is emerging as one of the fastest-growing markets globally.

India Shingles Vaccines Market Size

India is expected to make up 18% of the Asia Pacific shingles vaccines market in 2026, supported by expanding private healthcare infrastructure, increasing healthcare awareness, and a growing elderly population. Rising physician recommendations and improving access to adult vaccination services continue strengthening demand across metropolitan and tier-one cities.

Government efforts to enhance preventive healthcare, expanding hospital networks, and higher healthcare spending are supporting wider vaccine availability. Increasing diagnosis of age-related diseases, improving distribution channels, and growing acceptance of adult immunization are expected to reinforce India's position within the Asia Pacific shingles vaccines market.

Japan Shingles Vaccines Market Size

Japan is forecast to hold 31% of the Asia Pacific shingles vaccines market in 2026, driven by one of the world's oldest populations, strong healthcare infrastructure, and widespread awareness of herpes zoster prevention. National immunization initiatives and high physician confidence continue supporting broad adoption of recombinant shingles vaccines.

Government-backed adult vaccination programs, favorable reimbursement policies, and established preventive healthcare practices continue sustaining vaccine demand. Strong regulatory support, high healthcare expenditure, and increasing focus on healthy aging are anticipated to strengthen Japan's leadership within the Asia Pacific shingles vaccines market.

The global shingles vaccines market remains highly concentrated, dominated by GlaxoSmithKline plc., whose Shingrix vaccine commands the overwhelming majority of global sales following Zostavax's discontinuation. Competitive differentiation centers on manufacturing capacity expansion, clinical data generation supporting expanded eligibility criteria, and distribution partnership development across pharmacy and retail healthcare channels. Regional players including SK bioscience Co., Ltd. and GC Biopharma are pursuing domestic manufacturing strategies across Asian markets. Emerging vaccine technology developers continue exploring next-generation formulation approaches, signaling potential future competitive entry into this currently concentrated market landscape.

Key Industry Developments:

• In June 2026, GlaxoSmithKline plc. announced the launch of its Shingrix shingles vaccine in South Africa, marking its availability in the country's private healthcare sector nearly a decade after its initial U.S. introduction. The recombinant vaccine is expected to improve access to shingles prevention through private pharmacies, although its inclusion in South Africa's public healthcare system is not anticipated in the near term.
• In May 2026, Qatar University (QU), in collaboration with the Primary Health Care Corporation (PHCC), launched the "Protect the Ones Who Protected You" awareness campaign to encourage shingles vaccination among adults aged 50 years and older. The initiative promotes public awareness of herpes zoster prevention and supports wider adoption of the two-dose shingles vaccine, now available across all PHCC health centers in Qatar.
• In July 2025, GSK plc received the US Food and Drug Administration (FDA) approval for a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster). The new prefilled syringe removed the need to reconstitute separate vials prior to administration, simplifying the vaccination process for healthcare professionals.